BG98216A - Benzofuran derivatives - Google Patents
Benzofuran derivativesInfo
- Publication number
- BG98216A BG98216A BG98216A BG9821693A BG98216A BG 98216 A BG98216 A BG 98216A BG 98216 A BG98216 A BG 98216A BG 9821693 A BG9821693 A BG 9821693A BG 98216 A BG98216 A BG 98216A
- Authority
- BG
- Bulgaria
- Prior art keywords
- group selected
- alkyl
- 6alkyl
- group
- hydrogen
- Prior art date
Links
- 150000001907 coumarones Chemical class 0.000 title 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919110636A GB9110636D0 (en) | 1991-05-16 | 1991-05-16 | Chemical compounds |
| PCT/GB1992/000888 WO1992020674A1 (en) | 1991-05-16 | 1992-05-15 | 1h-imidazol-1-yl-methyl benzofuran derivatives, with the imidazolyl moiety being substituted by a cycloalkyl group |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG98216A true BG98216A (en) | 1994-08-15 |
Family
ID=10695121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG98216A BG98216A (en) | 1991-05-16 | 1993-11-12 | Benzofuran derivatives |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US5332831A (enExample) |
| EP (1) | EP0514198B1 (enExample) |
| JP (1) | JPH06211846A (enExample) |
| KR (1) | KR920021541A (enExample) |
| AP (1) | AP318A (enExample) |
| AT (1) | ATE169297T1 (enExample) |
| AU (2) | AU1692692A (enExample) |
| BG (1) | BG98216A (enExample) |
| CA (1) | CA2068766A1 (enExample) |
| CZ (1) | CZ243093A3 (enExample) |
| DE (1) | DE69226472D1 (enExample) |
| FI (1) | FI935036A7 (enExample) |
| GB (1) | GB9110636D0 (enExample) |
| IL (1) | IL101882A0 (enExample) |
| IS (1) | IS1609B (enExample) |
| MX (1) | MX9202281A (enExample) |
| NO (1) | NO921944L (enExample) |
| OA (1) | OA09841A (enExample) |
| SK (1) | SK112893A3 (enExample) |
| TW (1) | TW221998B (enExample) |
| WO (1) | WO1992020674A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9218449D0 (en) | 1992-08-29 | 1992-10-14 | Boots Co Plc | Therapeutic agents |
| US5336779A (en) * | 1992-10-08 | 1994-08-09 | Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha | Method of producing formylimidazoles |
| DK0853477T3 (da) * | 1995-10-06 | 2003-02-10 | Novartis Ag | AT1-receptor-antagonister til forebyggelse og behandling af postiskæmisk nyresvigt og til beskyttelse af iskæmiske nyrer |
| JP4369994B2 (ja) | 1996-02-29 | 2009-11-25 | ノバルティス アクチエンゲゼルシャフト | アポトーシスの刺激のためのａｔ▲下１▼レセプターアンタゴニスト |
| KR100567183B1 (ko) * | 1997-11-14 | 2006-06-13 | 론자 아게 | 포르밀이미다졸의제조방법 |
| US6465502B1 (en) | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| RU2271809C2 (ru) | 1998-12-23 | 2006-03-20 | Новартис Аг | Применение антагониста рецептора at-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2 |
| CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
| US6211217B1 (en) | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
| DE60037192T2 (de) * | 1999-07-21 | 2008-05-15 | Takeda Pharmaceutical Co. Ltd. | Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| US6794405B2 (en) * | 2000-08-17 | 2004-09-21 | Merck & Co., Inc. | Alicyclic imidazoles as H3 agents |
| DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| ES2560247T3 (es) * | 2006-05-05 | 2016-02-18 | Dow Global Technologies Llc | Complejos de hafnio de ligandos orgánicos heterocíclicos |
| AU2007292155B2 (en) | 2006-09-05 | 2012-11-01 | Kyowa Kirin Co., Ltd. | Imidazole derivative |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| JP5072675B2 (ja) | 2007-04-03 | 2012-11-14 | 四国化成工業株式会社 | ２−ハロイミダゾール化合物の製造方法 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CA2688161C (en) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| HK1220611A1 (zh) | 2013-03-15 | 2017-05-12 | Bausch Health Ireland Limited | 用於治疗胃肠道病症的组成物 |
| CN113388007A (zh) | 2013-06-05 | 2021-09-14 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| SI3648761T1 (sl) | 2017-07-07 | 2024-07-31 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartan za profilakso ali zdravljenje hipertenzije pri mačkah |
| CN110256382A (zh) * | 2019-06-06 | 2019-09-20 | 武汉药明康德新药开发有限公司 | 一种2-(5-甲基苯并呋喃-2-基)苯甲腈的合成方法 |
| CN121175053A (zh) | 2023-05-24 | 2025-12-19 | 勃林格殷格翰动物保健有限公司 | 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防 |
| WO2025125409A1 (en) | 2023-12-15 | 2025-06-19 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1389827A (en) * | 1971-07-23 | 1975-04-09 | Fisons Ltd | Tetrazolyl benzopyrans |
| JPS54148788A (en) * | 1978-05-15 | 1979-11-21 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation |
| US4526896A (en) * | 1978-12-26 | 1985-07-02 | Riker Laboratories, Inc. | Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof |
| JPS5671073A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| ZA824343B (en) * | 1981-07-01 | 1983-04-27 | Upjohn Co | Pyridinyl- and imidazolyl-benzofurane and benzothiophenes |
| JPS6163671A (ja) * | 1984-09-05 | 1986-04-01 | Shionogi & Co Ltd | ２，３−ジヒドロベンゾフラン−５−スルホンアミド誘導体および降圧利尿剤 |
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US4916129A (en) * | 1989-01-19 | 1990-04-10 | E. I. Du Pont De Nemours And Company | Combination β-blocking/angiotensin II blocking antihypertensives |
| EP0403159B1 (en) * | 1989-06-14 | 2000-03-01 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| WO1991000277A1 (en) * | 1989-06-30 | 1991-01-10 | E.I. Du Pont De Nemours And Company | Substituted imidazoles |
| KR950009860B1 (ko) * | 1989-06-30 | 1995-08-29 | 이. 아이. 듀퐁 드 네모아 앤드 캄파니 | 융합된 환 아릴 치환된 이미다졸과 약제학적으로 허용되는 이의 염, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물 |
| JPH03204875A (ja) * | 1989-10-03 | 1991-09-06 | Wakamoto Pharmaceut Co Ltd | テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤 |
| CA2027937A1 (en) * | 1989-10-25 | 1991-04-26 | Richard M. Keenan | Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles |
| CA2028925A1 (en) * | 1989-11-06 | 1991-05-07 | Gerald R. Girard | Substituted n-(imidazolyl)alkyl alanine derivatives |
| GB8927277D0 (en) * | 1989-12-01 | 1990-01-31 | Glaxo Group Ltd | Chemical compounds |
| US5190942A (en) * | 1991-04-22 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives |
| IL101888A0 (en) * | 1991-05-16 | 1992-12-30 | Glaxo Group Ltd | Benzofuran derivatives,their preparation and pharmaceutical compositions containing them |
| DE4140519A1 (de) * | 1991-12-09 | 1993-06-17 | Merck Patent Gmbh | Benzofurane |
-
1991
- 1991-05-16 GB GB919110636A patent/GB9110636D0/en active Pending
-
1992
- 1992-05-15 NO NO92921944A patent/NO921944L/no unknown
- 1992-05-15 MX MX9202281A patent/MX9202281A/es unknown
- 1992-05-15 IL IL101882A patent/IL101882A0/xx unknown
- 1992-05-15 US US07/883,378 patent/US5332831A/en not_active Expired - Fee Related
- 1992-05-15 AP AP9200389A patent/AP318A/en active
- 1992-05-15 TW TW081103782A patent/TW221998B/zh active
- 1992-05-15 WO PCT/GB1992/000888 patent/WO1992020674A1/en not_active Ceased
- 1992-05-15 AU AU16926/92A patent/AU1692692A/en not_active Abandoned
- 1992-05-15 CA CA002068766A patent/CA2068766A1/en not_active Abandoned
- 1992-05-15 CZ CS932430A patent/CZ243093A3/cs unknown
- 1992-05-15 AU AU16321/92A patent/AU654350B2/en not_active Ceased
- 1992-05-15 DE DE69226472T patent/DE69226472D1/de not_active Expired - Lifetime
- 1992-05-15 KR KR1019920008241A patent/KR920021541A/ko not_active Ceased
- 1992-05-15 IS IS3865A patent/IS1609B/is unknown
- 1992-05-15 AT AT92304420T patent/ATE169297T1/de not_active IP Right Cessation
- 1992-05-15 EP EP92304420A patent/EP0514198B1/en not_active Expired - Lifetime
- 1992-05-15 SK SK1128-93A patent/SK112893A3/sk unknown
- 1992-05-15 JP JP4148890A patent/JPH06211846A/ja active Pending
-
1993
- 1993-10-08 OA OA60424A patent/OA09841A/en unknown
- 1993-11-12 BG BG98216A patent/BG98216A/xx unknown
- 1993-11-15 FI FI935036A patent/FI935036A7/fi not_active Application Discontinuation
-
1994
- 1994-03-31 US US08/220,698 patent/US5498722A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2068766A1 (en) | 1992-11-17 |
| EP0514198A1 (en) | 1992-11-19 |
| NO921944D0 (no) | 1992-05-15 |
| EP0514198B1 (en) | 1998-08-05 |
| US5332831A (en) | 1994-07-26 |
| TW221998B (enExample) | 1994-04-01 |
| FI935036A0 (fi) | 1993-11-15 |
| FI935036A7 (fi) | 1993-11-15 |
| NO921944L (no) | 1992-11-17 |
| GB9110636D0 (en) | 1991-07-03 |
| JPH06211846A (ja) | 1994-08-02 |
| DE69226472D1 (de) | 1998-09-10 |
| AU654350B2 (en) | 1994-11-03 |
| WO1992020674A1 (en) | 1992-11-26 |
| AP318A (en) | 1994-02-15 |
| MX9202281A (es) | 1992-11-01 |
| IL101882A0 (en) | 1992-12-30 |
| SK112893A3 (en) | 1994-11-09 |
| AU1692692A (en) | 1992-12-30 |
| ATE169297T1 (de) | 1998-08-15 |
| OA09841A (en) | 1994-08-15 |
| IS3865A (is) | 1992-11-17 |
| KR920021541A (ko) | 1992-12-18 |
| AU1632192A (en) | 1993-03-11 |
| US5498722A (en) | 1996-03-12 |
| CZ243093A3 (en) | 1994-03-16 |
| IS1609B (is) | 1996-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG98216A (en) | Benzofuran derivatives | |
| FI884879A0 (fi) | Terapeutiskt anvaendbara heterocykliska foereningar. | |
| ATE247654T1 (de) | Neue heterozyklische verbindungen | |
| NO166126C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater. | |
| ATE128623T1 (de) | Mittel zur verbesserung von arzneimitteleffekten für antitumormittel. | |
| MX9202844A (es) | 1-indolilalquil-4-( alcoxi-pirimidinil) piperazinas y composicion farmaceutica que las contiene. | |
| NO163568C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater. | |
| KR910007883A (ko) | 퀴놀린 유도체, 그의 제조방법 및 용도 | |
| IE890177L (en) | Piperidinyl derivatives | |
| DE69227088D1 (de) | Verwendung von 1-(aminoalkyl)-3-Quinoxalin-2-on Derivaten zur Herstellung von neuroprotektiven Mitteln | |
| DE69105572D1 (de) | 4-Phenylphthalazin-Derivate. | |
| ATE158795T1 (de) | Thiazolidindionderivate, ihre herstellung und anwendung | |
| ATE225335T1 (de) | Amide derivate als 5-ht1a liganden | |
| DK0462933T3 (da) | Hidtil ukendte N-benzyl-N1-phenyl og -phenylalkyl-thiourinstoffer | |
| NO934741L (no) | Fremgangsmåte for minimalisering og kontroll av ischemiske og reperfusjonsskade | |
| DK0420224T3 (da) | Anthihepatopatisk middel | |
| ES2077697T3 (es) | Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos. | |
| DE3782229D1 (de) | Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten. | |
| UA35545C2 (uk) | Спосіб одержання похідних 4-оксохіноліну або хромону |